Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 4 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.
Sci Adv. 2022 Jan 7;8(1):eabh3827. doi: 10.1126/sciadv.abh3827. Epub 2022 Jan 7.
Sci Adv. 2022.
PMID: 34995117
Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T.
Miyamoto S, et al. Among authors: hemmi t.
Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4.
Med. 2022.
PMID: 35261995
Free PMC article.
Item in Clipboard
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T, Ainai A, Hashiguchi T, Tobiume M, Kanno T, Iwata-Yoshikawa N, Iida S, Sato Y, Miyamoto S, Ueno A, Sano K, Saito S, Shiwa-Sudo N, Nagata N, Tamura K, Suzuki R, Hasegawa H, Suzuki T.
Hemmi T, et al.
Vaccine. 2022 Sep 29;40(41):5892-5903. doi: 10.1016/j.vaccine.2022.08.049. Epub 2022 Aug 26.
Vaccine. 2022.
PMID: 36064667
Free PMC article.
Item in Clipboard
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T.
Miyamoto S, et al. Among authors: hemmi t.
iScience. 2023 Feb 17;26(2):105969. doi: 10.1016/j.isci.2023.105969. Epub 2023 Jan 13.
iScience. 2023.
PMID: 36687316
Free PMC article.
Item in Clipboard
Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses.
Kotani O, Suzuki Y, Saito S, Ainai A, Ueno A, Hemmi T, Sano K, Tabata K, Yokoyama M, Suzuki T, Hasegawa H, Sato H.
Kotani O, et al. Among authors: hemmi t.
Viruses. 2021 Aug 31;13(9):1733. doi: 10.3390/v13091733.
Viruses. 2021.
PMID: 34578314
Free PMC article.
Item in Clipboard
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Sonoyama T, Iwata S, Shinkai M, Iwata-Yoshikawa N, Shiwa-Sudo N, Hemmi T, Ainai A, Nagata N, Matsunaga N, Tada Y, Homma T, Omoto S, Yokokawa Shibata R, Igarashi K, Suzuki T, Hasegawa H, Ariyasu M.
Sonoyama T, et al. Among authors: hemmi t.
Vaccine. 2023 Mar 10;41(11):1834-1847. doi: 10.1016/j.vaccine.2022.12.025. Epub 2022 Dec 16.
Vaccine. 2023.
PMID: 36572603
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite